{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:47:33Z","timestamp":1794052053310,"version":"4.8.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32071413"],"award-info":[{"award-number":["32071413"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373261"],"award-info":[{"award-number":["82373261"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ymthe.2024.12.014","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T02:45:41Z","timestamp":1734057941000},"page":"688-702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-\u03b2 signal"],"prefix":"10.1016","volume":"33","author":[{"given":"Shen","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2688-9229","authenticated-orcid":false,"given":"Yun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3045-4428","authenticated-orcid":false,"given":"Hongkui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.12.014_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T\u00a0cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.12.014_bib2","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.12.014_bib3","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.12.014_bib4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.12.014_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-018-0119-y","article-title":"CAR T\u00a0cell therapy: inroads to response and resistance","volume":"19","author":"Brown","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nri2095","article-title":"TGFbeta signalling in control of T-cell-mediated self-reactivity","volume":"7","author":"Rubtsov","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/14728222.2019.1636034","article-title":"Blockade of TGF-\u03b2 signaling: a potential target for cancer immunotherapy","volume":"23","author":"Ungefroren","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ymthe.2024.12.014_bib8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs-from CTLA4 to PD1 to the next generations","volume":"15","author":"Hoos","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.12.014_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.12.014_bib10","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-Negative TGF-\u03b2 receptor enhances PSMA-Targeted human CAR T\u00a0cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.12.014_bib11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00262-022-03290-6","article-title":"Dominant-negative transforming growth factor-\u03b2 receptor-armoured mesothelin-targeted chimeric antigen receptor T\u00a0cells slow tumour growth in a mouse model of ovarian cancer","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2024.12.014_bib12","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T\u00a0cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.12.014_bib14","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.3390\/cancers12123586","article-title":"Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2024.12.014_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cytogfr.2006.05.001","article-title":"IL-15\/IL-15 receptor biology: A guided tour through an expanding universe","volume":"17","author":"Budagian","year":"2006","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2024.12.014_bib16","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T\u00a0cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.exphem.2016.06.003","article-title":"IL-2, IL-7, and IL-15: Multistage regulators of CD4(+) T helper cell differentiation","volume":"44","author":"Read","year":"2016","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.ymthe.2024.12.014_bib19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T\u00a0cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.12.014_bib20","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ni.2472","article-title":"IL-2 and IL-15 signaling complexes: Different but the same","volume":"13","author":"Ikemizu","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib21","article-title":"Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use","volume":"2017","author":"Van den Bergh","year":"2017","journal-title":"J.\u00a0Immunol. Res."},{"key":"10.1016\/j.ymthe.2024.12.014_bib22","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T\u00a0cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.12.014_bib23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","article-title":"Transgenic Expression of IL15 Improves Antiglioma Activity of IL13R\u03b12-CAR T Cells but Results in Antigen Loss Variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2024.12.014_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/1566523218666181116093857","article-title":"Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15R\u03b1 Signaling","volume":"19","author":"Nair","year":"2019","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.12.014_bib25","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.3390\/ijms23137311","article-title":"Interleukin 15 in Cell-Based Cancer Immunotherapy","volume":"23","author":"Zhou","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.12.014_bib26","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/08820139.2018.1480030","article-title":"Immunological examination of peripheral blood in patients with colorectal cancer compared to healthy controls","volume":"47","author":"Spacek","year":"2018","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.ymthe.2024.12.014_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2013.03.021","article-title":"Chimeric \u03b3c cytokine receptors confer cytokine independent engraftment of human T lymphocytes","volume":"56","author":"Hunter","year":"2013","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41551-023-01143-w","article-title":"Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T\u00a0cells via JAK\/STAT signalling","volume":"8","author":"Bell","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2024.12.014_bib29","doi-asserted-by":"crossref","first-page":"8706","DOI":"10.3390\/ijms22168706","article-title":"TGF-\u03b2\/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma","volume":"22","author":"Noh","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.12.014_bib30","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-012-1212-x","article-title":"Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor","volume":"61","author":"Sahm","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2024.12.014_bib31","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.4049\/jimmunol.1300433","article-title":"Cutting edge: Smad2 and Smad4 regulate TGF-\u03b2-mediated Il9 gene expression via EZH2 displacement","volume":"191","author":"Wang","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1522471","article-title":"TGF-\u03b2 enhances the cytotoxic activity of V\u03b42 T\u00a0cells","volume":"8","author":"Peters","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2024.12.014_bib33","doi-asserted-by":"crossref","first-page":"5902","DOI":"10.1038\/s41467-020-19672-2","article-title":"Enhanced CAR-T activity against established tumors by polarizing human T\u00a0cells to secrete interleukin-9","volume":"11","author":"Liu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.12.014_bib34","doi-asserted-by":"crossref","first-page":"735","DOI":"10.21037\/atm.2019.12.03","article-title":"Preclinical safety evaluation of chimeric antigen receptor-modified T\u00a0cells against CD19 in NSG mice","volume":"7","author":"Wen","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.12.014_bib35","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.annonc.2020.10.474","article-title":"Local delivery of CAR T\u00a0cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial","volume":"32","author":"Hiltbrunner","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib36","article-title":"Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study","volume":"11","author":"Papa","year":"2023","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2024.12.014_bib37","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib38","first-page":"513","article-title":"Large- and small-molecule inhibitors of transforming growth factor-beta signaling","volume":"7","author":"Akhurst","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ymthe.2024.12.014_bib39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12032-023-02204-5","article-title":"TGF-\u03b2 in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer","volume":"40","author":"Singh","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib40","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.2174\/138920111798808392","article-title":"Antibody targeting of TGF-\u03b2 in cancer patients","volume":"12","author":"Lonning","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib41","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/0192623311416259","article-title":"Induction of heart valve lesions by small-molecule ALK5 inhibitors","volume":"39","author":"Anderton","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib42","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood-2005-12-4827","article-title":"Differential regulation of T-cell growth by IL-2 and IL-15","volume":"108","author":"Cornish","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.12.014_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2013.01.004","article-title":"Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2024.12.014_bib44","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1073\/pnas.0307298101","article-title":"IL-15 enhances the in\u00a0vivo antitumor activity of tumor-reactive CD8+ T\u00a0cells","volume":"101","author":"Klebanoff","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.12.014_bib45","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4049\/jimmunol.1600019","article-title":"IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector\/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists","volume":"197","author":"Desbois","year":"2016","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/2326-6066.CIR-15-0009","article-title":"The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy","volume":"3","author":"Waldmann","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2024.12.014_bib47","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.add1219","article-title":"Structural basis of \u03b3 chain family receptor sharing at the membrane level","volume":"381","author":"Cai","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.12.014_bib48","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.cellsig.2013.06.001","article-title":"Transforming growth factor-\u03b2 signalling: role and consequences of Smad linker region phosphorylation","volume":"25","author":"Kamato","year":"2013","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ymthe.2024.12.014_bib49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/abbs\/gmx126","article-title":"TGF-\u03b2 family co-receptor function and signaling","volume":"50","author":"Nickel","year":"2018","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"10.1016\/j.ymthe.2024.12.014_bib50","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.4049\/jimmunol.169.7.3600","article-title":"IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response","volume":"169","author":"Strengell","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib51","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fimmu.2014.00174","article-title":"How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?","volume":"5","author":"Haabeth","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib52","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3389\/fimmu.2014.00607","article-title":"Tumor-Infiltrating \u03b3\u03b4 T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programing in the Tumor Microenvironment","volume":"5","author":"Lo Presti","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib53","doi-asserted-by":"crossref","first-page":"E5444","DOI":"10.1073\/pnas.1604256113","article-title":"IL2R\u03b2-dependent signals drive terminal exhaustion and suppress memory development during chronic viral infection","volume":"113","author":"Beltra","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.12.014_bib54","article-title":"Off-the-shelf V\u03b41 gamma delta T\u00a0cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma","volume":"9","author":"Makkouk","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2024.12.014_bib55","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: a systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib56","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10555-006-9006-2","article-title":"Transforming growth factor-beta in cancer and metastasis","volume":"25","author":"Jakowlew","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ymthe.2024.12.014_bib57","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2024.12.014_bib58","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2024.12.014_bib59","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2024.12.014_bib60","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.12.014_bib61","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.12.014_bib62","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1182\/blood-2014-01-551671","article-title":"Long-term outcome after haploidentical stem cell transplant and infusion of T\u00a0cells expressing the inducible caspase 9 safety transgene","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.12.014_bib63","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.ymthe.2024.12.014_bib64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/hum.2018.180","article-title":"A Cetuximab-Mediated Suicide System in Chimeric Antigen Receptor-Modified Hematopoietic Stem Cells for Cancer Therapy","volume":"30","author":"Kao","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2024.12.014_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.728962","article-title":"CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report","volume":"12","author":"Sun","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib66","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/genbio.2023.0024","article-title":"Comparative Evaluation of Synthetic Cytokines for Enhancing Production and Performance of NK92 Cell-Based Therapies","volume":"2","author":"Deol","year":"2023","journal-title":"GEN. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib67","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1073\/pnas.1405514111","article-title":"IL-15.IL-15R\u03b1 complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T\u00a0cells","volume":"111","author":"Tamzalit","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.12.014_bib68","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T\u00a0cells by gamma(c) family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib69","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028449","article-title":"The Common Cytokine Receptor \u03b3 Chain Family of Cytokines","volume":"10","author":"Lin","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib70","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cytogfr.2014.07.018","article-title":"The IL-2 cytokine family in cancer immunotherapy","volume":"25","author":"Sim","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2024.12.014_bib71","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/imr.12644","article-title":"The role of cytokines in T-cell memory in health and disease","volume":"283","author":"Raeber","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2024.12.014_bib72","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cytogfr.2018.05.002","article-title":"The role of the common gamma-chain family cytokines in \u03b3\u03b4 T\u00a0cell-based anti-cancer immunotherapy","volume":"41","author":"Van Acker","year":"2018","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2024.12.014_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.101307","article-title":"Common gamma chain cytokines and CD8 T\u00a0cells in cancer","volume":"42","author":"Shourian","year":"2019","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib74","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/1078-0432.CCR-09-1303","article-title":"Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy","volume":"16","author":"Sport\u00e8s","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.12.014_bib75","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/biom12091303","article-title":"Co-Stimulatory Receptor Signaling in CAR-T Cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2024.12.014_bib76","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12967-023-04372-4","article-title":"Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality","volume":"21","author":"Smith","year":"2023","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.ymthe.2024.12.014_bib77","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2024.12.014_bib78","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.12.014_bib79","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1158\/2326-6066.CIR-19-0115","article-title":"Metabolic Consequences of T-cell Costimulation in Anticancer Immunity","volume":"7","author":"Teijeira","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2024.12.014_bib80","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T\u00a0cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.12.014_bib81","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.12.014_bib82","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.12.014_bib83","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.12.014_bib84","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1158\/0008-5472.CAN-06-2098","article-title":"CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T\u00a0cells in an antitumor cell attack","volume":"67","author":"Koehler","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2024.12.014_bib85","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ymthe.2018.07.005","article-title":"CD28-\u03b6 CAR T Cells Resist TGF-\u03b2 Repression through IL-2 Signaling, Which Can Be Mimicked by an Engineered IL-7 Autocrine Loop","volume":"26","author":"Golumba-Nagy","year":"2018","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162400813X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162400813X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:54:22Z","timestamp":1770252862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162400813X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S152500162400813X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.014","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potentiating CAR-T cell function in the immunosuppressive tumor microenvironment by inverting the TGF-\u03b2 signal","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}